The company trying to make cell therapy a manufacturing problem.

Somewhere in a closed, sterile loop on Main Street in Cambridge, a few billion human cells are flowing past an electric field. Each one gets nudged open for a fraction of a second, takes in a payload of CRISPR or mRNA, and seals back up - alive, ideally annoyed but unharmed. Then a few billion more. This is Kytopen on an ordinary Tuesday: not curing anyone directly, but building the machine that makes the cure possible to make.

That distinction is the whole company. Cell therapies - CAR-T, engineered NK cells, edited stem cells - already pull off things that read like science fiction. They also tend to cost a fortune and take an eternity, because the step where you actually get genetic instructions into the cells is slow, finicky, and rough on the cells themselves. Kytopen's bet is that this one unglamorous step is the bottleneck holding back an entire field.

The problem they saw

A bottleneck dressed up as a science problem

For decades, getting genes into cells meant one of two unappealing choices. You could use a virus - effective, but expensive to manufacture, slow to produce, and saddled with safety paperwork. Or you could use electroporation, which zaps cells with electricity in a static cuvette. It works, but it is harsh: cells die, yields drop, and what works for a few million cells in a lab rarely scales cleanly to the billions a clinical batch demands.

The cruel irony is that the science of what to put in the cells raced ahead - CRISPR, base editing, clever mRNA cargo - while the question of how to deliver it at scale stayed stuck. A therapy can be brilliant on a bench and still be impossible to manufacture for the thousandth patient. Kytopen looked at that gap and decided it was an engineering problem, not a biology one.

The founders' bet

A DARPA grant about bacteria, of all things

Kytopen's origin is delightfully off-target. In 2013, MIT mechanical engineering professor Cullen Buie won a DARPA Young Faculty Award to work on getting genetic material into bacterial cells. That funding let him hire postdoc Paulo Garcia, who brought deep expertise in electric fields. Buie brought microfluidics. Together they had a method that combined flowing fluid with electricity - and a use case that, at the time, had nothing to do with human medicine.

Then they did the unglamorous thing founders are always told to do and rarely manage: they listened. Through the NSF I-Corps program, they interviewed people in industry, and the same question kept surfacing - can it work on T cells? When they incorporated in 2017, the market had quietly redrawn their map. Bacteria were out. Mammalian cells, and the cell-therapy boom, were in.

The product

Flowfect: three forces, one tunable dial

The thing Kytopen sells is called Flowfect, and its trick is that it stops treating delivery as a single brute-force zap. Instead of holding cells still and shocking them, Flowfect flows them past electric fields in a continuous stream, blending three forces at once - mechanical (the flow), electrical (the field), and chemical. Each one is a dial you can turn to balance transfection efficiency against cell health and yield.

That continuous-flow design is what lets it scale. The product line walks a customer from curiosity to clinic: Flowfect Discover, a 96-well system for screening conditions across cell types and payloads; and Flowfect Tx, a GMP-ready platform built to process billions of cells in minutes inside a closed, automated loop. The pitch is that you optimize on one box and manufacture on the next without re-inventing your process - the part of cell therapy that usually breaks.

The proof

Receipts, not just slides

Claims about gentleness and scale are easy to make and hard to believe, which is why the most useful thing Kytopen has is independent data. Charles River Laboratories ran a comparative study pitting Flowfect Tx against two conventional electroporation platforms in a CRISPR/Cas9 TRAC knockout in primary T cells. The verdict, per the study: greater cell viability and editing efficiency. When a CDMO you don't control says your box works, that travels further than a brochure.

The receipts stack up elsewhere too. A Phase II NIH/NIAID SBIR Fast-Track grant of $1.6M backs work on engineered natural killer cells. A collaboration with Bio-Techne wires the TcBuster transposon system into the Flowfect workflow. Cambridge Consultants helped engineer the Tx system itself. And the platform has been tapped for the GMP manufacture of an engineered cell therapy heading toward the clinic - the moment a research tool graduates into something patients depend on.

The mission

Make the cure boring to manufacture

Kytopen's stated ambition is almost anticlimactic, which is the point: take payload delivery - fast, gentle, scalable, reproducible - and turn it from a research art into a manufacturing step. The vision underneath is bigger. If engineered cells can be made affordably and at scale, then therapies that today reach a lucky few could reach the many. The bottleneck Kytopen attacks is technical; the consequence is access.

It is run now by CEO Michael Chiu, Ph.D., who joined in 2023 with a commercialization brief, while co-founder Cullen Buie remains an MIT professor - a rare case where the microfluidics lab and the factory floor share a bloodline. The April 2026 Series B, led by Telegraph Hill Partners, is explicitly about going global: more customers, more instruments, more of the unglamorous infrastructure that turns a promising box into a standard one.

Why it matters tomorrow

Back to the loop on Main Street

Return to that closed loop in Cambridge, the one with billions of cells streaming past an electric field. A decade ago, that scene would have been a graduate student, a cuvette, a lot of dead cells, and a result that fell apart the moment anyone tried to make a thousand doses of it. Now it is a continuous, automated process designed from the start to be copied - the same on the discovery bench and the GMP floor.

That is the change Kytopen is chasing. Not a louder miracle, but a repeatable one. A world where the limiting factor in cell therapy is no longer whether you can make enough cells, but only what you choose to teach them to do. The biology was never the hard part. Kytopen is busy with the part that was.